Verve Therapeutics Inc (NASDAQ: VERV) kicked off on Friday, down -10.97% from the previous trading day, before settling in for the closing price of $5.38. Over the past 52 weeks, VERV has traded in a range of $4.30-$19.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 126.44%. While this was happening, its average annual earnings per share was recorded 21.22%. With a float of $63.09 million, this company’s outstanding shares have now reached $81.97 million.
Let’s determine the extent of company efficiency that accounts for 255 employees. In terms of profitability, gross margin is 73.07%, operating margin of -928.6%, and the pretax margin is -806.35%.
Verve Therapeutics Inc (VERV) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 26.23%, while institutional ownership is 69.37%. The most recent insider transaction that took place on May 14 ’24, was worth 475,760. In this transaction an insider of this company bought 76,000 shares at a rate of $6.26, taking the stock ownership to the 342,509 shares. Before that another transaction happened on Apr 02 ’24, when Company’s Chief Administrative Officer sold 1,514 for $8.24, making the entire transaction worth $12,475. This insider now owns 8,659 shares in total.
Verve Therapeutics Inc (VERV) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 21.22% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Take a look at Verve Therapeutics Inc’s (VERV) current performance indicators. Last quarter, stock had a quick ratio of 13.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.79 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Looking closely at Verve Therapeutics Inc (NASDAQ: VERV), its last 5-days average volume was 2.29 million, which is a jump from its year-to-date volume of 1.33 million. As of the previous 9 days, the stock’s Stochastic %D was 5.16%. Additionally, its Average True Range was 0.46.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 13.27%, which indicates a significant increase from 0.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.39% in the past 14 days, which was lower than the 77.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.45, while its 200-day Moving Average is $7.45. However, in the short run, Verve Therapeutics Inc’s stock first resistance to watch stands at $5.23. Second resistance stands at $5.66. The third major resistance level sits at $5.89. If the price goes on to break the first support level at $4.57, it is likely to go to the next support level at $4.34. Now, if the price goes above the second support level, the third support stands at $3.91.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
The company with the Market Capitalisation of 361.07 million has total of 84,664K Shares Outstanding. Its annual sales at the moment are 11,760 K in contrast with the sum of -200,070 K annual income. Company’s last quarter sales were recorded 6,870 K and last quarter income was -50,130 K.
